Shares in German biopharma Affimed dropped near 30% after the company said it was placing a key Phase I programme of its experimental cancer immunotherapy on hold because of serious side effects observed in trials, including a patient death.
Shares in UK speciality pharma Diurnal plummeted more than 50 percent on news that a late-stage study of an experimental treatment for congenital adrenal hyperplasia (CAH) failed to meet its primary objective.
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
The highly anticipated Medical & Scientific Excellence Awards close for entry in just a few weeks (31 October). This is your chance to stand out against the competition, enter now to get the recognition you deserve.
The Medicines and Healthcare products Regulatory Agency has launched a consultation seeking views on how its legislation and regulatory processes would have to be modified if the UK leaves the EU under a ‘no-deal’ scenario.